Alexion Pharmaceuticals Inc

ALXN 
(NASDAQ) 
 
$ 127.55
Updated 01:00:01
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 733,434
High $ 130.01
Low $ 126.30
Open $ 129.63
ISIN
Prev close $ 129.84
# of shares 223.47M
Market cap 28,504M USD
Intraday

Market closed
Alexion Pharmaceuticals Inc
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  127.55 -1.4% Stock price decreasing 11.6% Stock price increasing 8.0% Stock price increasing 8.4% Stock price increasing 11.3% Stock price increasing
Powered by TradingView

News about Alexion Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Alexion Pharmaceuticals specializes in developing and marketing drugs for life-threatening medical conditions. Its blockbuster product is Soliris, which is the only approved therapy for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, two ultra-rare blood disorders, and was recently approved in general myasthenia gravis. Strensiq and Kanuma target other ultra-rare metabolic diseases. Alexion's pipeline targets areas of high unmet need and complement-mediated disorders.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 09:18:32
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB6 - 2019-02-22 10:18:32 - 2019-02-22 09:18:32 - 1000 - Website: OKAY